专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006066878A1 PREVENTION OF THROMBUS FORMATION AND/OR STABILIZATION 审中-公开
标题翻译：防止血栓形成和/或稳定
公开(公告)号：WO2006066878A1
公开(公告)日：2006-06-29
申请号：PCT/EP2005/013714
申请日：2005-12-20
申请人： NIESWANDT, Bernhard , RENNE, Thomas
发明人： NIESWANDT, Bernhard , RENNE, Thomas
IPC分类号： A61P7/02 , A61K39/395 , A61K38/56 , C07K16/36 , C07K14/81
CPC分类号： C07K16/36 , A61K38/55 , A61K38/556 , A61K38/56 , A61K38/57 , A61K39/3955 , A61K2039/505 , C07K16/40 , C07K2317/76 , Y02A50/414
摘要： The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and preventing the formation and/or the stabilization of threedimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
摘要翻译：本发明涉及至少一种抗体和/或一种抑制剂用于抑制因子XII并防止三维血栓的形成和/或稳定化的用途。它还涉及药物制剂和使用因子XII作为抗血栓形成靶标。

2. 发明申请

WO2011003809A1 ROLE OF PLD1 IN THROMBUS FORMATION AND INTEGRIN ALPHA IIB BETA 3 ACTIVATION 审中-公开
标题翻译： PLD1在血栓形成和INTEGRIN ALPHA IIB BETA 3激活中的作用
公开(公告)号：WO2011003809A1
公开(公告)日：2011-01-13
申请号：PCT/EP2010/059405
申请日：2010-07-01
申请人： CSL BEHRING GMBH , JULIUS-MAXIMILIANS-UNIVERSITÄT-WÜRZBURG , NIESWANDT, Bernhard , STOLL, Guido
发明人： NIESWANDT, Bernhard , STOLL, Guido
IPC分类号： C07K16/40 , C12N9/20 , A61K39/395 , G01N33/50
CPC分类号： C07K16/40 , A01K2217/075 , A61K2039/505 , C12N9/20
摘要： The present invention relates to an inhibitor of phospholipase D1(PLD1) or an inhibitor of a direct activator of PLD1 for use in treating or preventing a disorder related to venous or arterial thrombus formation. Alternatively the present invention relates to the use of such an inhibitor as a lead compound for developing a drug for treating or preventing a disorder related to venous or arterial thrombus formation. The present invention also relates to a method of treating and/or preventing a disorder related to venous or arterial thrombus formation comprising administering a pharmaceutically effective amount of an inhibitor of phospholipase D1(PLD1) or an inhibitor of a direct activator of PLD1 to a subject in need thereof. The present invention further relates to methods of identifying a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of a disorder related to venous or arterial thrombus formation.
摘要翻译：本发明涉及磷脂酶D1（PLD1）的抑制剂或PLD1的直接活化剂的抑制剂，其用于治疗或预防与静脉或动脉血栓形成相关的病症。或者，本发明涉及这种抑制剂作为引导化合物用于开发用于治疗或预防与静脉或动脉血栓形成相关的病症的药物的用途。本发明还涉及治疗和/或预防与静脉或动脉血栓形成相关的病症的方法，其包括向受试者施用药学有效量的磷脂酶D1（PLD1）抑制剂或PLD1直接激活剂的抑制剂需要它。本发明还涉及鉴定适合作为铅化合物的化合物和/或用于治疗和/或预防与静脉或动脉血栓形成相关的障碍的药物的方法。

3. 发明申请

WO2003103662A3 INHIBITORS OF GLYCOPROTEIN VI 审中-公开
公开(公告)号：WO2003103662A3
公开(公告)日：2003-12-18
申请号：PCT/EP2003/005919
申请日：2003-06-05
申请人： PROCORDE GMBH , MASSBERG, Steffen , GAWAZ, Meinrad , NIESWANDT, Bernhard , BÜLTMANN, Andreas , MÜNCH, Götz , UNGERER, Martin , PELUSO, Mario , GRÜNER, Sabine
发明人： MASSBERG, Steffen , GAWAZ, Meinrad , NIESWANDT, Bernhard , BÜLTMANN, Andreas , MÜNCH, Götz , UNGERER, Martin , PELUSO, Mario , GRÜNER, Sabine
IPC分类号： C07K16/28
摘要： The Invention provides use of an antibody against platelet glycoprotein VI (GPVI) for the preparation of a medicament for the prevention of intraarterial thrombosis in a Patient characterized by (i) having suffered from an acute coronary or carotid syndrome and (ü)having active intraarterial lesions. The present Invention also provides an antibody against platelet glycoprotein VI (GPVI) for the preparation of a medicament for the manufacture of a medicament for the treatment of diabetes. Further, in vivo and in vivo screening methods for inhibitors or GP VI are provided and inhibitors identified thereby.

4. 发明申请

WO2010149664A1 CLEC-2 IS AN ESSENTIAL PLATELET ACTIVATING RECEPTOR IN HEMOSTASIS AND THROMBOSIS 审中-公开
标题翻译： CLEC-2是HEMOSTASIS和THROMBOSIS中的基础药物活化受体
公开(公告)号：WO2010149664A1
公开(公告)日：2010-12-29
申请号：PCT/EP2010/058840
申请日：2010-06-22
申请人： CSL Behring GmbH , Julius-Maximilians-Universität-Würzburg , NIESWANDT, Bernhard , MAY, Frauke
发明人： NIESWANDT, Bernhard , MAY, Frauke
IPC分类号： A61P7/02
CPC分类号： G01N33/5044 , A61K39/39541 , A61K39/3955 , A61K2039/505 , C07K16/2803 , C07K2317/55 , C07K2319/30 , G01N2333/4724 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition comprising an inhibitor of C-type lectin-like receptor 2 (CLEC-2) or an inhibitor of an activator of CLEC-2, each of which induces an irreversible inactivation or degradation of CLEC-2 on platelets, and optionally a pharmaceutically acceptable carrier, excipient and/or diluent. Furthermore, the present invention relates to an inhibitor of C-type lectin-like receptor 2 (CLEC-2) or an inhibitor of an activator of CLEC-2, each of which induces an irreversible inactivation or degradation of CLEC-2 on platelets, for use in treating or preventing a disorder related to venous or arterial thrombus formation and to the use of such an inhibitor as a lead compound for developing a drug for treating or preventing a disorder related to venous or arterial thrombus formation. The present invention also relates to a method of treating and/or preventing a disorder related to venous or arterial thrombus formation comprising administering a pharmaceutically effective amount of an inhibitor of C-type lectin-like receptor 2 (CLEC-2) or an inhibitor of an activator of CLEC-2, each of which induces an irreversible inactivation or degradation of CLEC-2 on platelets, to a subject in need thereof. The present invention further relates to methods of identifying a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of a disorder related to venous or arterial thrombus formation.
摘要翻译：本发明涉及包含C型凝集素样受体2（CLEC-2）抑制剂或CLEC-2活化剂抑制剂的药物组合物，其各自诱导CLEC-2的不可逆失活或降解血小板和任选的药学上可接受的载体，赋形剂和/或稀释剂。此外，本发明涉及C型凝集素样受体2（CLEC-2）的抑制剂或CLEC-2的活化剂的抑制剂，其各自诱导血小板上的CLEC-2的不可逆失活或降解，用于治疗或预防与静脉或动脉血栓形成相关的病症，以及使用这种抑制剂作为引导化合物用于开发用于治疗或预防与静脉或动脉血栓形成相关的病症的药物。本发明还涉及治疗和/或预防与静脉或动脉血栓形成相关的病症的方法，其包括给予药学有效量的C型凝集素样受体2（CLEC-2）抑制剂或 CLEC-2的活化剂，其各自诱导血小板上的CLEC-2的不可逆失活或降解，需要其受试者。本发明还涉及鉴定适合作为铅化合物的化合物和/或用于治疗和/或预防与静脉或动脉血栓形成相关的障碍的药物的方法。

5. 发明申请

WO2010136577A1 STIM2-MEDIATED CAPACITIVE CALCIUM ENTRY 审中-公开
标题翻译： STIM2介导的电容钙入侵
公开(公告)号：WO2010136577A1
公开(公告)日：2010-12-02
申请号：PCT/EP2010/057443
申请日：2010-05-28
申请人： CSL BEHRING GMBH , JULIUS-MAXIMILIANS-UNIVERSITÄT-WÜRZBURG , NIESWANDT, Bernhard , STOLL, Guido
发明人： NIESWANDT, Bernhard , STOLL, Guido
IPC分类号： A61K39/395 , C07K16/18 , C12N15/113
CPC分类号： C07K16/18 , A61K39/39541 , C07K14/705
摘要： The present invention relates to a pharmaceutical composition comprising an inhibitor of STIM2 or an inhibitor of STIM2-regulated plasma membrane calcium channel activity and optionally a pharmaceutically acceptable carrier, excipient and/or diluent. Furthermore, the present invention relates to an inhibitor of STIM2 or an inhibitor of STIM2-regulated plasma membrane calcium channel activity for the treatment and/or prevention of a neurological disorder associated with pathologically increased cytosolic calcium concentrations. The present invention also relates to a method of treating and/or preventing a neurological disorder associated with pathologically increased cytosolic calcium concentrations comprising administering a pharmaceutically effective amount of an inhibitor of STIM2 or of an inhibitor of STIM2-regulated plasma membrane calcium channel activity to a subject in need thereof. The present invention further relates to methods of identifying a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of a neurological disorder associated with pathologically increased cytosolic calcium concentrations.
摘要翻译：本发明涉及包含STIM2抑制剂或STIM2调节的质膜钙通道活性抑制剂和任选的药学上可接受的载体，赋形剂和/或稀释剂的药物组合物。此外，本发明涉及用于治疗和/或预防与病理性增加的细胞溶质钙浓度相关的神经障碍的STIM2抑制剂或STIM2调节的质膜钙通道活性抑制剂。本发明还涉及治疗和/或预防与病理增加的细胞溶质钙浓度相关的神经障碍的方法，其包括将药物有效量的STIM2抑制剂或STIM2调节的质膜钙通道活性抑制剂施用于受到需要。本发明还涉及鉴定适合作为铅化合物的化合物和/或用于治疗和/或预防与病理增加的细胞溶质钙浓度相关的神经障碍的药物的方法。

6. 发明申请

WO2003103662A2 INHIBITORS OF GLYCOPROTEIN VI 审中-公开
标题翻译：葡萄糖苷VI的抑制剂
公开(公告)号：WO2003103662A2
公开(公告)日：2003-12-18
申请号：PCT/EP2003/005919
申请日：2003-06-05
申请人： PROCORDE GMBH , MASSBERG, Steffen , GAWAZ, Meinrad , NIESWANDT, Bernhard , BÜLTMANN, Andreas , MÜNCH, Götz , UNGERER, Martin , PELUSO, Mario , GRÜNER, Sabine
发明人： MASSBERG, Steffen , GAWAZ, Meinrad , NIESWANDT, Bernhard , BÜLTMANN, Andreas , MÜNCH, Götz , UNGERER, Martin , PELUSO, Mario , GRÜNER, Sabine
IPC分类号： A61K31/4035
CPC分类号： C07K14/745 , A61K38/00 , A61K47/6811 , A61K2039/505 , C07K14/70503 , C07K16/2803 , C07K19/00 , C07K2319/00 , C07K2319/30 , C12N2799/021 , G01N33/5088 , G01N33/86 , Y02A50/407
摘要： The Invention provides use of an antibody against platelet glycoprotein VI (GPVI) for the preparation of a medicament for the prevention of intraarterial thrombosis in a Patient characterized by (i) having suffered from an acute coronary or carotid syndrome and (ü)having active intraarterial lesions. The present Invention also provides an antibody against platelet glycoprotein VI (GPVI) for the preparation of a medicament for the manufacture of a medicament for the treatment of diabetes. Further, in vivo and in vivo screening methods for inhibitors or GP VI are provided and inhibitors identified thereby.
摘要翻译：本发明提供抗血小板糖蛋白VI（GPVI）的抗体用于制备用于预防患者动脉内血栓形成的药物，其特征在于：（i）患有急性冠状动脉或颈动脉综合征，和（ü）具有活动动脉内病变。本发明还提供了抗血小板糖蛋白VI（GPVI）的抗体，用于制备用于制备用于治疗糖尿病的药物的药物。此外，提供了用于抑制剂或GP VI的体内和体内筛选方法，由此鉴定出抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式